Browse FREM2

Summary
SymbolFREM2
NameFRAS1 related extracellular matrix protein 2
Aliases DKFZp686J0811; ECM3 homolog; FRAS1-related extracellular matrix protein 2
Chromosomal Location13q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Extracellular side
Domain PF03160 Calx-beta domain
Function

Extracellular matrix protein required for maintenance of the integrity of the skin epithelium and for maintenance of renal epithelia. May be required for epidermal adhesion.

> Gene Ontology
 
Biological Process GO:0007423 sensory organ development
GO:0007507 heart development
GO:0043583 ear development
GO:0048839 inner ear development
Molecular Function -
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005604 basement membrane
GO:0044420 extracellular matrix component
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolFREM2
NameFRAS1 related extracellular matrix protein 2
Aliases DKFZp686J0811; ECM3 homolog; FRAS1-related extracellular matrix protein 2
Chromosomal Location13q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FREM2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolFREM2
NameFRAS1 related extracellular matrix protein 2
Aliases DKFZp686J0811; ECM3 homolog; FRAS1-related extracellular matrix protein 2
Chromosomal Location13q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FREM2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFREM2
NameFRAS1 related extracellular matrix protein 2
Aliases DKFZp686J0811; ECM3 homolog; FRAS1-related extracellular matrix protein 2
Chromosomal Location13q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FREM2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0270.961
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.610.498
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4070.589
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6730.281
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.2250.506
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0240.992
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0260.977
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5210.697
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5920.672
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2830.709
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2580.792
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.8650.0477
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FREM2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 1417011.8-11.80.488
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.716.4-12.70.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 014014.3-14.31
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.716.9-13.20.161
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211728.611.816.80.257
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)862516.78.31
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131130.89.121.70.327
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382713.211.12.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.623.1-9.50.648
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.5012.50.485
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFREM2
NameFRAS1 related extracellular matrix protein 2
Aliases DKFZp686J0811; ECM3 homolog; FRAS1-related extracellular matrix protein 2
Chromosomal Location13q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FREM2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFREM2
NameFRAS1 related extracellular matrix protein 2
Aliases DKFZp686J0811; ECM3 homolog; FRAS1-related extracellular matrix protein 2
Chromosomal Location13q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FREM2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FREM2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFREM2
NameFRAS1 related extracellular matrix protein 2
Aliases DKFZp686J0811; ECM3 homolog; FRAS1-related extracellular matrix protein 2
Chromosomal Location13q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FREM2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFREM2
NameFRAS1 related extracellular matrix protein 2
Aliases DKFZp686J0811; ECM3 homolog; FRAS1-related extracellular matrix protein 2
Chromosomal Location13q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FREM2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFREM2
NameFRAS1 related extracellular matrix protein 2
Aliases DKFZp686J0811; ECM3 homolog; FRAS1-related extracellular matrix protein 2
Chromosomal Location13q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FREM2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFREM2
NameFRAS1 related extracellular matrix protein 2
Aliases DKFZp686J0811; ECM3 homolog; FRAS1-related extracellular matrix protein 2
Chromosomal Location13q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FREM2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.